Cost-conscious payers are eyeing higher prices on diabetes drugs

Tracy Staton

A time-honored technique for boosting drug sales is simple: Raise . Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable price hikes on may be backfiring with . With diabetes costs taking double-digit increases–and expensive newer meds launching–insurers are tightening restrictions on drug use.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS